company background image
A067630

HLB Life Science KOSDAQ:A067630 Stock Report

Last Price

₩9.06k

Market Cap

₩922.4b

7D

-2.8%

1Y

-25.8%

Updated

23 Sep, 2023

Data

Company Financials

HLB Life Science Co., Ltd.

KOSDAQ:A067630 Stock Report

Mkt Cap: ₩922.4b

A067630 Stock Overview

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally.

A067630 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis


HLB Life Science Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HLB Life Science
Historical stock prices
Current Share Price₩9,060.00
52 Week High₩13,320.00
52 Week Low₩8,260.00
Beta0.55
1 Month Change5.35%
3 Month Change-8.11%
1 Year Change-25.85%
3 Year Change-30.45%
5 Year Change-14.93%
Change since IPO425.70%

Recent News & Updates

HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Apr 12
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Recent updates

HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Apr 12
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?

Feb 14
Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?

Is HLB Life Science (KOSDAQ:067630) A Risky Investment?

Jan 10
Is HLB Life Science (KOSDAQ:067630) A Risky Investment?

We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings

Dec 06
We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings

Shareholder Returns

A067630KR HealthcareKR Market
7D-2.8%-4.7%-3.8%
1Y-25.8%-1.7%11.0%

Return vs Industry: A067630 underperformed the KR Healthcare industry which returned -1.7% over the past year.

Return vs Market: A067630 underperformed the KR Market which returned 11% over the past year.

Price Volatility

Is A067630's price volatile compared to industry and market?
A067630 volatility
A067630 Average Weekly Movement5.4%
Healthcare Industry Average Movement6.4%
Market Average Movement5.9%
10% most volatile stocks in KR Market12.3%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A067630 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A067630's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199897Sung-Bo Simhttps://www.hlb-ls.com

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood.

HLB Life Science Co., Ltd. Fundamentals Summary

How do HLB Life Science's earnings and revenue compare to its market cap?
A067630 fundamental statistics
Market Cap₩922.36b
Earnings (TTM)-₩46.63b
Revenue (TTM)₩120.36b

7.7x

P/S Ratio

-19.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A067630 income statement (TTM)
Revenue₩120.36b
Cost of Revenue₩123.11b
Gross Profit-₩2.75b
Other Expenses₩43.88b
Earnings-₩46.63b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-457.99
Gross Margin-2.28%
Net Profit Margin-38.74%
Debt/Equity Ratio64.8%

How did A067630 perform over the long term?

See historical performance and comparison